NCT05650216 2022-12-14
Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）
Shanghai Chest Hospital
Phase 2 Unknown
Clinical Trials
10 trialsNCT05322499 2022-04-11
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04506138 2021-12-14
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital
Phase 1/2 Unknown
NCT04654403 2021-08-23
Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer
The First Affiliated Hospital of Zhengzhou University
Phase NA Unknown
NCT04984018 2021-07-30
Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT03766178 2021-07-07
Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04866381 2021-04-29
An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04767295 2021-02-23
A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)
Hunan Cancer Hospital
Phase 2 Unknown
NCT03603756 2020-02-11
SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer
ChineseAMS
Phase 2 Unknown
NCT03817658 2019-01-25
A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown